A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.
Epistemonikos ID: 697b60011edd6929b3ecf69aed1c431da84451da
First added on: Feb 19, 2024